Alternative Data for TherapeuticsMD
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,508 | Sign up | Sign up | Sign up |
| X Followers | 627 | Sign up | Sign up | Sign up |
| X Mentions | 3 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 51 | Sign up | Sign up | Sign up |
About TherapeuticsMD
TherapeuticsMD Inc is a women's health care company focused on creating and commercializing products targeted exclusively for women. It is engaged in pre-commercialization activities for advanced hormone therapy pharmaceutical product.
| Price | $2.30 |
| Target Price | Sign up |
| Volume | 48,110 |
| Market Cap | $27M |
| Year Range | $1.04 - $2.77 |
| Dividend Yield | 0% |
| PE Ratio | 236 |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
Bioidentical Hormones Market Size to Reach USD 5.51 Billion by 2033, Driven by Personalized Hormone Therapy Adoption and Rising Menopausal Care Demand – SNS InsiderJanuary 27 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 780,000 | 96,000 | 690,000 | 150,000 | 150,000 | 0.000 |
| Q2 '25 | 950,000 | 96,000 | 950,000 | 550,000 | -220,000 | 0.050 |
| Q1 '25 | 390,000 | 130,000 | 390,000 | -650,000 | -690,000 | 0.022 |
| Q4 '24 | 670,000 | 0 | 670,000 | 250,000 | -970,000 | 0.022 |
| Q3 '24 | 550,000 | 0 | 550,000 | -610,000 | -760,000 | -0.053 |
Insider Transactions View All
| Thompson Tommy G filed to buy 23,179 shares at $1.7. December 29 '25 |
| Walker Marlan D filed to buy 73,639 shares at $1. April 15 '25 |
| Thompson Tommy G filed to buy 14,779 shares at $1. April 15 '25 |
| Walker Marlan D filed to buy 73,149 shares at $0.9. April 10 '25 |
| Walker Marlan D filed to buy 71,982 shares at $0.9. April 10 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$243.33 0% | 63 |
 |
Eli Lilly and CompanyLLY |
$1036.05 0% | 73 |
 |
PfizerPFE |
$27.37 0% | 44 |
 |
AstrazenecaAZN |
$209.48 0% | 63 |
 |
AbbVieABBV |
$232.86 0% | 65 |
Read more about TherapeuticsMD (TXMD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - TherapeuticsMD
The Market Cap of TherapeuticsMD is $27M.
As of today, TherapeuticsMD's PE (Price to Earnings) ratio is 236.
Currently, the price of one share of TherapeuticsMD stock is $2.30.
The TXMD stock price chart above provides a comprehensive visual representation of TherapeuticsMD's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TherapeuticsMD shares. Our platform offers an up-to-date TXMD stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, TherapeuticsMD (TXMD) does not offer dividends to its shareholders. Investors interested in TherapeuticsMD should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of TherapeuticsMD are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
